Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
HEALTHY PARTICIPANTS: No
LOCATION: UH Cleveland Medical Center
The purpose of this study is to evaluate recurrence-free survival in participants with resected pancreatic neuroendocrine tumors (pNETs) randomized to treatment with capecitabine + temozolomide (CAPTEM) compared to observation only.
Who Can Participate
Participants 18 years old and older diagnosed with diagnosed with pancreatic neuroendocrine carcinoma or have metastatic malignant neoplasm in the liver may be eligible for this study.